Criteria for Severe Major Depressive Disorder
Diagnostic Criteria
- Severe major depressive disorder is diagnosed when a patient meets DSM criteria for MDD and demonstrates marked severity on standardized rating scales or clinical presentation, as recommended by the American Psychiatric Association 1
- A Hamilton Depression Rating Scale (HAM-D) score >23 indicates severe depression, according to the American Psychiatric Association 2, 3
- Marked impairment in work, social, or self-care functioning is a key characteristic of severe major depressive disorder, as noted by the American Psychiatric Association 1
Initial Treatment for Severe Major Depression
- The American College of Physicians recommends initiating combination treatment with both an SSRI and cognitive behavioral therapy for severe major depressive disorder, as this approach provides superior outcomes compared to monotherapy 4, 5
- The American Psychiatric Association suggests starting sertraline 50 mg once daily as the preferred first-line SSRI due to well-established efficacy and favorable tolerability, with a strength of evidence rated as high 5
Treatment Outcomes
- The response to treatment is defined as ≥50% reduction in HAM-D score, and remission is defined as HAM-D score ≤7, according to the American Psychiatric Association 2, 3
- The American College of Physicians recommends continuing treatment for 4-9 months after achieving remission to prevent relapse, with a moderate strength of evidence 4
- The American Psychiatric Association suggests maintaining treatment for ≥1 year in patients with multiple prior episodes to prevent recurrence, with a high strength of evidence 4
Common Pitfalls to Avoid
- The American College of Physicians advises against using antidepressant monotherapy as sole treatment for severe depression when combination with psychotherapy is feasible, as this leaves therapeutic benefit on the table, with a high strength of evidence 5
- The American Psychiatric Association recommends avoiding paroxetine as first-line agent due to higher rates of sexual dysfunction compared to other SSRIs, with a moderate strength of evidence 4